Alkermes ALKS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Alkermes (ALKS) Business Model and Operations Summary
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Key Insights
Alkermes (ALKS) Core Market Data and Business Metrics
Latest Closing Price
$32.53Market Cap
$5.28 BillionPrice-Earnings Ratio
-15.20Total Outstanding Shares
162.61 Million SharesTotal Employees
1,800Dividend
No dividendIPO Date
July 16, 1991SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
Connaught House, Dublin 4, L2, 00000
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-43,000 |
| Net Cash Flow From Investing Activities | $-43,000 |
| Net Cash Flow, Continuing | $-47.87 Million |
| Net Cash Flow From Operating Activities | $-47.77 Million |
| Net Cash Flow | $-47.87 Million |
| Net Cash Flow From Financing Activities | $-59,000 |
Income Statement
October 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Interest Income/Expense After Provision For Losses | $5.39 Million |
| Operating Expenses | $67.02 Million |
| Basic Earnings Per Share | $-1.07 |
| Net Income/Loss Available To Common Stockholders, Basic | $-57.96 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Diluted Average Shares | $15,000 |
Comprehensive Income
October 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-57.96 Million |
| Comprehensive Income/Loss Attributable To Parent | $-57.96 Million |
| Other Comprehensive Income/Loss | $0 |
Balance Sheet
October 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $11.68 Million |
| Wages | $14.47 Million |
| Other Current Liabilities | $26.26 Million |
| Other Non-current Assets | $58.62 Million |
| Fixed Assets | $3.08 Million |
| Equity | $486.93 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||